CEO Grandidier has transformed Xeltis from a small research entity into one of the most promising medical device companies globally. Xeltis is pioneering a restorative approach in heart valve therapy. Under his leadership, the company closed an oversubscribed Series C financing round of €45 million in 2017.

1. **HE IS VISIONARY**

   Today Xeltis is pioneering a restorative approach in heart valve therapy. From his initial involvement with Xeltis, Grandidier immediately recognized the game-changing potential of its technology. Shortly after joining, Grandidier drove the pivoting of the business plan for the newly defined Xeltis, to focus R&D on Endogenous Tissue Restoration (ETR). This decision led to the transformation of Xeltis into today’s technology platform company. Grandidier's vision, drive and leadership skills have been recognized with the closing of Xeltis’ Series C financing round, the largest investment round for a private medical device company in Europe in 2017. The Xeltis approach has the potential to disrupt the entire cardiovascular sector: it challenges several preconceived ideas about what the body can do, how tissue restoration works and what medical devices can do.

2. **HE IS EXPERIENCED**

   To lead Xeltis’ pioneering business, Grandidier has harnessed his skills from leadership roles at global medtech companies, such as Endosense, Teleflex and Guidant. He started his career at Procter & Gamble, holds an MSC from INSA-Lyon and an MBA from INSEAD. Grandidier used his expertise to assist Xeltis in overcoming skepticism from several stakeholders; as such Xeltis has spent years building a growing body of evidence and hard science supporting the RestoreX technology; with unparalleled long-term animal studies and fundamental science. This fundamental work is driving the value of the company. Xeltis is not operating in the traditional medtech paradigm, in which speed from bench to bedside is the priority; cutting corners is not an option. Xeltis is actively involved in research collaborations with leading academic partners. Grandidier was voted Outstanding.

3. **HE IS A SOCIAL ENTREPRENEUR**

   Grandidier’s passionate entrepreneurial approach extends beyond Xeltis. In 2011, he co-founded one of the first French social venture capital funds, Investir&+, where he sits on the supervisory board. Laurent’s commitment to giving back is demonstrated through Xeltis’ engagement with and supporting of a number of patient associations under his leadership. These include Dutch organizations De Hart&Vaatgroep, Stichting Heartbeat and Hotel Heppie, and U.S. Mended Little Hearts, among others. For Grandidier, Xeltis represents a unique opportunity to make a real difference in the lives of patients who need cardiovascular treatment. In Grandidier’s own words Xeltis is working make the “seemingly impossible, possible.”